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Chronic TLR Stimulation Controls 
NLRP3 Inflammasome Activation 
through IL-10 Mediated Regulation 
of NLRP3 Expression and 
Caspase-8 Activation
Prajwal Gurung1, Bofeng Li2, R. K. Subbarao Malireddi1, Mohamed Lamkanfi3,4, 
Terrence L. Geiger2 & Thirumala-Devi Kanneganti1
While the molecular mechanisms promoting activation of the Nod-like Receptor (NLR) family 
member NLRP3 inflammasome are beginning to be defined, little is known about the mechanisms 
that regulate the NLRP3 inflammasome. Acute (up to 4 hours) LPS stimulation, followed by ATP is 
frequently used to activate the NLRP3 inflammasome in macrophages. Interestingly, we observed 
that the ability of LPS to license NLRP3 is transient, as prolonged (12 to 24 hours) LPS exposure 
was a relatively ineffective priming stimulus. This suggests that relative to acute LPS, chronic 
LPS exposure triggers regulatory mechanisms to dampen NLRP3 activation. Transfer of culture 
supernatants from macrophages stimulated with LPS for 24 hours dramatically reduced ATP- and 
nigericin-induced NLRP3 inflammasome activation in naïve macrophages. We further identified IL-10 
as the secreted inflammasome-tolerizing factor that acts in an autocrine manner to control activation 
of the NLRP3 inflammasome. Finally, we demonstrated that IL-10 dampens NLRP3 expression to 
control NLRP3 inflammasome activation and subsequent caspase-8 activation. In conclusion, we have 
uncovered a mechanism by which chronic, but not acute, LPS exposure induces IL-10 to dampen 
NLRP3 inflammasome activation to avoid overt inflammation.
The immune system is equipped with a set of pathogen recognition receptors (PRRs) that function to 
mount an immune response against invading pathogens. Toll-like receptors (TLRs) recognize patho-
gen associated molecular patterns (PAMPs) in the extracellular milieu and endosomes, while Nod-like 
receptors (NLRs) patrol the cytoplasm1. A set of Nod-like receptors that include NLRP1b, NLRP3 and 
NLRC4 assemble multi-protein complexes termed inflammasomes2–6. Inflammasome assembly is critical 
for activation of caspase-1, which ultimately cleaves pro-IL-1β and pro-IL-18 into their mature bioactive 
forms6. Because of their potent inflammatory activities, IL-1β and IL-18 are regulated at multiple levels7. 
Specifically, two signals are required for the activation of inflammasomes and the release of bioactive 
IL-1β and IL-18. The first step involves recognition of PAMPs such as LPS, PGN and polyI:C by TLRs 
to induce the priming signals that are necessary for upregulation of inflammasome components and 
pro-IL-1β . In the second step, recognition of cytoplasmic danger signals by NLRs results in assembly of 
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the inflammasome that processes pro-IL-1β and pro-IL-187,8. This coordinated regulation of the inflam-
masomes is necessary to limit unwanted inflammatory responses.
Inflammatory responses are akin to a double-edged sword and our immune system has several regu-
latory checkpoints to control these responses; too little and the pathogens take over or too much and the 
hyperinflammatory responses cause tissue damage. Aptly so, our immune system employs several nega-
tive feedback pathways to shut down inflammatory responses to avoid excessive damage to self-tissues. 
Once TLRs are activated by their cognate PAMPs, robust activation of NFκ B and MAP kinase signaling 
pathways induce upregulation of several hundred genes, mostly of the proinflammatory signature9–12. 
Studies tracking the time course of proinflammatory cytokine mRNA expression levels has shown that 
these mRNAs get upregulated as early as 30 minutes post TLR stimulation, peak within a couple of hours 
and return to basal expression by 4–6 hours13,14. This coordinated regulation of the pro-inflammatory 
gene expression is necessary to avoid unwanted inflammation and several mechanisms contribute to the 
negative regulation of these pathways15.
Once stimulated with TLR ligands, macrophages become refractory to subsequent challenge with 
similar ligands. This phenomenon is now widely referred to as endotoxin tolerance or LPS tolerance16. 
Studies have shown that similar tolerance can be achieved with stimulation of other TLRs and NLRs 
such as TLR2, TLR5, TLR9 and NOD217–20. While much is known about the negative regulation of 
inflammatory signaling and cytokine production during TLR stimulation, whether inflammasomes are 
also similarly regulated is not known. Here, we utilized a well-established LPS (1st signal–priming)/ATP 
(2nd signal- NLR activation) stimulation protocol to study activation of the NLRP3 inflammasome. Our 
study demonstrates that while acute LPS stimulation (4 h) induces robust NLRP3 inflammasome activa-
tion, chronic LPS stimulation (12 h–24 h) results in attenuation of the NLRP3 inflammasome. We further 
identify IL-10 as a soluble secreted factor that acts through a negative feedback loop to dampen NLRP3 
inflammasome activation. Our studies have thus uncovered a role for IL-10 in tempering activation of 
the NLRP3 inflammasome in response to chronic TLR stimulation.
Results
Chronic TLR engagement negatively regulates NLRP3 inflammasome activation. Prolonged 
LPS stimulation results in the inhibition of proinflammatory gene expression to avoid excessive inflam-
mation14,21. Recent study by Schroder et al. has shown that duration of LPS priming could adversely affect 
the activation of caspase-1 and IL-1β by ATP and nigericin22. To examine whether we could recapitulate 
similar phenomenon during NLRP3 inflammasome activation, BMDMs were stimulated with LPS for 
different periods of time before being exposed to 5 mM ATP for 30 minutes (Fig. 1A). As expected, mac-
rophages stimulated with LPS for 4 h responded to ATP treatment with robust caspase-1 activation as 
evident by the appearance of the activation-associated 20 kDa (p20) fragment in caspase-1 Western blots 
(Fig.  1A). Interestingly, prolonged LPS stimulation reduced caspase-1 processing in a time-dependent 
fashion, and caspase-1 maturation was dramatically reduced in lysates of ATP-treated BMDMs that had 
been stimulated with LPS for 24 h (Fig. 1A). In addition to preventing caspase-1 processing, prolonged 
LPS treatment also reduced ATP-induced secretion of mature IL-1β and IL-18 in the culture superna-
tants (Fig. 1C,D).
To address whether prolonged LPS exposure specifically interfered with ATP-induced activation of 
the NLRP3 inflammasome, we examined its effect on caspase-1 processing by nigericin. As expected, 
BMDMs treated with LPS for 4 h responded with robust nigericin-induced caspase-1 processing (Fig. 1B), 
and secretion of IL-1β (Fig.  1C) and IL-18 (Fig.  1D). However, these responses were all dramatically 
blunted in macrophages that had been exposed to LPS for 12–24 h (Fig. 1A–D). To address whether the 
concentration of LPS mattered in regulating the NLRP3 inflammasome, we stimulated BMDMs with low 
(1 and 10 ng/ml) or high (100 and 1000 ng/ml) concentrations of LPS for the indicated period of times 
(Supplementary Fig. S1). LPS induced robust caspase-1 activation in a dose dependent manner at early 
time points, which were similarly reduced at chronic time points (Supplementary Fig. S1). In addition to 
LPS, prolonged TLR2 engagement with PAM3CSK4 also diminished ATP-induced caspase-1 activation 
and IL-1β release (Supplementary Fig. S2), suggesting that the regulation of NLRP3 inflammasome fol-
lowing chronic stimulation is not specific to TLR4 alone. All these responses were specific and required 
both priming (LPS/PAM3CSK4) and activation signals (ATP/nigericin), since LPS, PAM3CSK4, ATP or 
nigericin alone did not induce caspase-1 activation or IL-1β production (Fig. 1 and Supplementary Fig. S2). 
To determine whether chronic TLR stimulation affected expression of IL-1β and IL-18, we stimulated 
BMDMs with LPS or PAM3CSK4 for 4, 12 and 24 h and assessed the levels of pro-IL1β and pro-IL-18 by 
Western blot. Our experiments showed that LPS or PAM3CSK4 stimulation for 24 h reduced the levels 
of pro-IL-1β , however pro-IL-18 levels increased in a time dependent manner (Supplementary Fig. S3). 
These results show that chronic TLR2 or TLR4 stimulation can directly regulate IL-1β levels, however, 
IL-18 levels are regulated through inflammasome-mediated processing.
Secreted factors are responsible for chronic LPS-induced control of NLRP3 inflammasome 
activation. Type I IFNs have been suggested to inhibit NLRP3 inflammasome23. Our studies showed 
that caspase-1 activation and IL-1β production were reduced to the same extent in chronic LPS-stimulated 
Ifnar−/− BMDMs (Supplementary Fig. S4). Caspase-11 has also been shown to be involved in regu-
lating NLRP3 inflammasome24. Stimulation of WT and Casp11−/− BMDMs further demonstrated that 
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caspase-11 is not involved in chronic LPS-mediated dampening of NLRP3 inflammasome (Supplementary 
Fig. S5). LPS stimulation leads to upregulation of both intracellular and secreted factors. To investi-
gate the mechanism by which chronic LPS exposure limits potent NLRP3 inflammasome activation, we 
examined whether factors in the culture supernatants of BMDMs treated with LPS for 24 h could prevent 
NLRP3 inflammasome activation by naïve macrophages. As expected, macrophages treated with LPS for 
4 h followed by ATP stimulation in fresh culture medium resulted in robust caspase-1 activation and 
pronounced secretion of high levels of IL-1β and IL-18. These inflammasome readouts were markedly 
reduced when cells were treated similarly in culture medium of BMDMs that have been exposed to LPS 
for 24 h, but not with culture medium of unstimulated or acute LPS-treated BMDMs (Fig. 2A–C). These 
results suggested that chronic LPS stimulation induces extracellular release of a soluble factor that limits 
NLRP3 inflammasome activation in naïve macrophages.
IL-10 is a well-established regulatory cytokine that suppresses and controls inflammation25. 
Furthermore, secretome analysis of supernatants from LPS-stimulated macrophages revealed IL-10 to 
be secreted with prolonged, but not short LPS treatment26. More importantly, study of Il10−/− BMDMs 
suggested that IL-10 regulates pro-IL-1β expression23. Additionally, studies with Il10−/− mice and neu-
tralizing IL10R signaling in WT mice showed enhanced expression of NLRP3 inflammasome compo-
nents in an antigen-induced arthritis model27. To investigate whether IL-10 was involved in chronic LPS 
stimulation-induced suppression of the NLRP3 inflammasome, we first examined the levels of IL-10 
in the supernatants of BMDMs stimulated for 4 and 24 hours. We found that the production of IL-10 
increased in a time-dependent manner (Fig. 2D–G and Supplementary Fig. S6). Importantly, PAM3CSK4 
Figure 1. Chronic LPS stimulation weakly activates NLRP3 inflammaome activation. Wildtype (WT) 
BMDMs were stimulated with LPS for 4, 12 and 24 hours followed by ATP or nigericin for the last 
30 minutes. (A,B) BMDMs were stimulated with LPS/ATP or LPS/Nigericin as indicated and lysates were 
blotted for caspase-1 and actin. Cell supernatants collected after LPS/ATP or LPS/Nigericin stimulations 
were analyzed by ELISA for IL-1β (C) and IL-18 (D). Solid arrow represents pro-form and open arrow 
represents cleaved-form of the protein in Western blots. ELISA data are presented as means ± s.e.m. of 
technical replicates and all data are representative of at least three independent experiments.
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stimulation also upregulated secreted levels of IL-10 with prolonged stimulation, which indicates that 
this is not specific to LPS (Fig. 2G and Supplementary Fig. S6A). Interestingly, chronic LPS stimulation 
also significantly increased IL-10R expression (Supplementary Fig. S6B–D). Collectively, these results 
imply that IL-10 may contribute to negative regulation of the NLRP3 inflammasome upon chronic TLR 
stimulation.
IL-10 negatively regulates NLRP3 inflammasome activation during chronic LPS treatment. 
To ascertain if the enhanced IL-10 production associated with chronic LPS stimulation is responsi-
ble for tempering of NLRP3 inflammasome activation, BMDMs were pre-incubated with recombinant 
IL-10 prior to stimulation with LPS. Addition of IL-10 prior to acute LPS/ATP stimulation significantly 
reduced, but did not completely abolish, the levels of processed caspase-1 and secreted IL-1β and IL-18 
in macrophages (Fig.  3A–C). Dramatic reduction of NLRP3 inflammasome activation by recombinant 
IL-10 was also observed when cells were primed with LPS for 12 h prior to ATP stimulation (Fig. 3A–C). 
In addition to reducing IL-1β cleavage, IL-10 also reduced the levels of pro-IL-1β suggesting a negative 
regulatory role for IL-10 in priming (Fig.  3A). Thus, our results suggest that IL-10 production upon 
chronic LPS exposure suppresses NLRP3 inflammasome activation. To further characterize the role of 
IL-10 in dampening the NLRP3 inflammasome, we utilized Il10raMdel mice that specifically lack IL-10R 
expression in macrophages28. As shown before, wild type BMDMs treated with LPS for 12 h were sig-
nificantly impaired in their ability to induce caspase-1 processing and IL-1β cleavage in response to 
Figure 2. Secreted factors produced during chronic LPS stimulations reduce NLRP3 inflammasome 
activation. (A–C) Control supernatant, 4 h supernatant and 24 h supernatants from LPS stimulated samples 
were added to fresh BMDMs and stimulated with LPS/ATP for 4 h. Caspase-1 activation (A), IL-1β release 
(B) and IL-18 release (C) were determined. (D–F) WT BMDMs were stimulated with LPS for 4 or 24 h and 
supernatants were collected. IL-10 and CCL1 in the 4 and 24 h supernatants were determined by cytokine 
profiler reverse Western kit (R&D systems). (D) IL-10 and CCL1 blots for 4 and 24 h supernatants. (E) IL-10 
band intensity normalized to 4 h IL-10 levels. (F) CCL1 levels normalized to 4 h CCL1 levels. (G) BMDMs 
were stimulated with LPS or PAM3CSK4 for 4 and 24 h followed by ATP/nigericin for the last 30 minutes. 
IL-10 in the supernatants of stimulated samples was determined by ELISA. Solid arrow represents pro-
form and open arrow represents cleaved-form of the protein in Western blots. ELISA data represent 
means ± s.e.m. and data are cumulative of at least three-five independent experiments. All other data are 
representative of at least three independent experiments. Statistical significance was determined by Student’s 
t test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Uncropped blots of represented western blots 
are presented in Supplementary Fig. 11 and 12.
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ATP. In marked contrast, prolonged LPS treatment failed to dampen NLRP3 inflammasome-mediated 
activation of caspase-1 and IL-1β cleavage in Il10raMdel BMDMs (Fig.  3D). In agreement, Il10raMdel 
BMDMs treated with LPS/ATP for 12 h secreted amounts of IL-1β and IL-18 in their culture medium 
that were comparable to those of macrophages treated with LPS/ATP for 4 h (Fig. 3E,F). In addition to 
Figure 3. IL-10 negatively regulates NLRP3 inflammasome activation. (A–C) WT BMDMs were 
pretreated with recombinant murine IL-10 for 30 minutes followed by LPS for indicated hours (4 h, 12 h) and 
ATP for the last 30 minutes. (A) Cell lysates were immunoblotted for caspase-1, IL-1β and GAPDH. Cell 
supernatants were collected and analyzed for IL-1β (B) and IL-18 (C) by ELISA. (D–F) WT and Il10raMdel 
(Macrophage specific deletion of IL-10R) BMDM were plated and stimulated with LPS for 4 h and 12 h 
followed by ATP for the last 30 minutes. (D) Caspase-1 activation, IL-1β cleavage, and GAPDH expression 
were determined in the cell lysates by Western blot. Cell supernatants were collected and analyzed for IL-1β 
(E) and IL-18 (F) by ELISA. Solid arrow represents pro-form and open arrow represents cleaved-form of the 
protein in Western blots. ELISA data represent means ± s.e.m. from three-five independent experiments and 
all other data are representative of at least three independent experiments. Uncropped blots of represented 
Western blots are presented in Supplementary Fig. 11.
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the use of Il10raMdel BMDMs, we also stimulated BMDMs with LPS for 4 or 12 h in the presence of IL-10 
receptor-neutralizing antibodies (α IL-10R Ab) to inhibit IL-10 signaling. α IL-10R Ab treatment rescued 
caspase-1 activation in WT BMDMs that were treated with LPS/ATP for 12 h (Supplementary Fig. S7A). 
Concurrently, the levels of secreted IL-1β and IL-18 in 12 h LPS treated BMDMs were markedly increased 
by α IL-10R Ab treatment, and reached levels comparable to those of cells exposed to LPS for only 4 h 
(Supplementary Fig. S7B,C). Together, these observations suggest that IL-10 signaling negatively regu-
lates NLRP3 inflammasome activation.
IL-10 suppresses NLRP3 inflammasome activation by regulating caspase-8 activation and 
NLRP3 expression. Our studies demonstrate that the IL-10 signaling pathway is critical for regu-
lating NLRP3 inflammasome activation during chronic TLR stimulations (Fig.  3). We have previously 
demonstrated links between the NLRP3 inflammasome and caspase-8 activity29. Thus, we were interested 
to investigate whether IL-10 abrogated caspase-1 activation by regulating caspase-8 activation. To this 
end, we examined caspase-8 activation in LPS/ATP stimulated BMDMs that were treated with exogenous 
IL-10 or impaired in IL-10R signaling (Il10raMdel). Robust caspase-8 activation was observed during acute 
LPS stimulations and this caspase-8 activation was reduced in chronic stimulations (Fig. 4A,B). While 
IL-10 pretreatment did not impact caspase-8 activation at acute time points (4 h LPS), IL-10 attenu-
ated caspase-8 activation at chronic time points (12 h LPS) (Fig. 4A and Supplementary Fig. S8A). This 
caspase-8 processing was specific to NLRP3 inflammasome activation since LPS or ATP stimulation alone 
did not induce caspase-8 activation (Supplementary Fig. S8C). Furthermore, acute PAM3CSK4+ ATP 
stimulation also induces caspase-8 activation (Supplementary Fig. S8C). In contrast, caspase-8 activation 
was dramatically increased in Il10raMdel BMDMs at both acute and chronic time points (Fig.  4B and 
Supplementary Fig. S8B).
Both NLRP3 and ASC are required for LPS/ATP induced caspase-8 activation29. We proposed that 
IL-10 might be regulating the expression of either ASC or NLRP3 to control caspase-8 activation. ASC 
expression remained unchanged during LPS stimulation in the presence or absence of IL-10 signaling, 
suggesting that IL-10 does not regulate ASC expression (Fig.  4A,B). To examine whether chronic LPS 
stimulation limits NLRP3 expression, we stimulated BMDMs with LPS for either 4 or 16 hours in the 
presence or absence of exogenous IL-10 and NLRP3 protein levels were assessed. Acute LPS stimula-
tion increased NLRP3 protein levels, however, this was reduced with chronic LPS stimulation (Fig. 4C). 
Moreover, addition of exogenous IL-10 dramatically dampened LPS-induced NLRP3 expression follow-
ing stimulation at both 4 and 16 hours (Fig. 4D). IL-10 controlled both IL-1β and NLRP3 expression by 
decreasing LPS-induced mRNA expression of these proteins (Supplementary Fig. S9A,B). In contrast, 
α IL-10R Ab treatment of WT BMDMs rescued NLRP3 expression at chronic time points (Fig.  4E). 
Similarly, chronic LPS stimulation did not reduce the expression of NLRP3 in Il10raMdel macrophages 
(Fig. 4F). Collectively, these results indicate that chronic LPS stimulation-induced IL-10 dampens NLRP3 
inflammasome activation in part by regulating the NLRP3 expression and caspase-8 activation.
Discussion
NLRP3 is one of the best-studied Nod-like receptors that forms an inflammasome, a multimeric protein 
complex that mediates processing of pro-IL-1β and pro-IL-18 into their mature forms30. NLRP3 inflam-
masomes are assembled in response to a wide array of stimuli including bacteria, viruses and fungi; as 
well as danger-associated signals such as ATP and nigericin. Infection or stimulation of cells ultimately 
results in K+ efflux and Ca2+ mobilization that activates the NLRP3 inflammasome31,32. Although studies 
characterizing the activation of NLRP3 inflammasomes are abundant, the factors regulating the NLRP3 
inflammasomes are less clear. While several studies have suggested that IL-10 can inhibit NLRP3 inflam-
masome23,27,33, the dynamics of acute and chronic TLR stimulation and how that impacts NLRP3 inflam-
masome was less clear. Herein, we demonstrate that IL-10 works in a negative feedback loop to regulate 
NLRP3 inflammasome activation during chronic stimulations (Supplementary Fig. S10).
Previous work has shown that IFN-β induces IL-10 production through the IFNAR signaling pathway 
that involves STAT123. Upstream of IFN-β , the TLR-TRIF signaling axis is critically involved in IFN-β 
production34. Thus, it could be argued that TLR-induced IFN-β production is responsible for induction of 
IL-10 synthesis through the IFNAR signaling axis. However, we see negative regulation of NLRP3 inflam-
masome during chronic PAM3CSK4 stimulation (Supplementary Fig. S2), which does not engage the 
TRIF pathway. Furthermore, chronic LPS stimulation induces similar reduction of caspase-1 activation 
and IL-1β production in Ifnar2−/− BMDMs (Supplementary Fig. S4). This suggests that TLR-stimulation 
induced IL-10 and control of NLRP3 inflammasome is independent of the IFNAR signaling axis.
IL-10 has previously been shown to promote endotoxin tolerance in macrophages, where tolerized 
macrophages fail to produce proinflammatory cytokines upon re-challenge25,35. While we have only 
shown that chronic TLR-2 and TLR-4 stimulation induces IL-10 and regulates NLRP3 inflammasome, 
other studies have shown that IFNAR signaling, especially IFNβ induces IL-1023. Thus, it is possible that 
chronic stimulation through another TLR that engages TRIF (TLR-3) might also abrogate the NLRP3 
inflammasome. IL-10 is a regulatory cytokine that is known for its negative role in inflammation. As 
such, Il10−/− mice exhibit hyperinflammation and are susceptible to inflammatory bowel disease36. IL-10 
has also been reported to inhibit NFκ B and MAP kinases, and thus control inflammation37,38. Our stud-
ies demonstrated that the ability of IL-10 to inhibit NLRP3-mediated IL-1β secretion is in part due to 
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its regulation of pro-IL-1β expression. While IL-10 did not appear to significantly alter the expression 
of ASC, our work further revealed a role for IL-10 in regulating inflammasome activation by regulat-
ing NLRP3 expression (Fig.  4). IL-10 induced reduction of NLRP3 could be attributed to enhanced 
proteasomal degradation of NLRP3, or inhibition of Nlrp3 mRNA expression. Our studies with IL-10 
pretreatment of WT BMDMs suggest that IL-10 negatively regulates mRNA expression of both Il1b and 
Nlrp3 (Supplementary Fig. S9).
Figure 4. IL-10 regulates caspase-8 activation and NLRP3 levels to modulate NLRP3 inflammasome 
activation during chronic LPS stimulations. (A) WT BMDMs were pretreated with recombinant murine 
IL-10 for 30 minutes followed by LPS for 4 or 12 h and ATP for the last 30 minutes. Cell lysates were 
immunoblotted for ASC, caspase-8 and GAPDH. (B) WT and Il10raMdel BMDMs were plated and stimulated 
with LPS for 4 and 12 h followed by ATP for the last 30 minutes. ASC, caspase-8 activation and GAPDH 
expression were determined in the cell lysates by Western blot. Solid arrow represents pro-form and open 
arrow represents cleaved-form of the protein in Western blots. (C) WT or Nlrp3−/− BMDMs were stimulated 
with LPS for 4 and 16 h. NLRP3 and GAPDH expression was determined by Western blot. WT BMDMs 
were pretreated with recombinant murine IL-10 (D) or α IL-10R Ab (E) for 30 minutes followed by LPS for 
4 or 16 h. Cell lysates were immunoblotted for NLRP3 and GAPDH. (F) WT and Il10raMdel BMDM were 
treated with LPS for 4 and 16 h. Cell lysates were blotted for NLRP3 and GAPDH. All data are representative 
of at least three independent experiments. Uncropped blots of represented Western blots are presented in 
Supplementary Fig. 11.
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The IL-10/IL-10R signaling axis plays a central role in modulating inflammation. Genome wide asso-
ciation studies identified the IL-10 signaling axis as one of the important factors in conferring suscepti-
bility to colitis39. In agreement, humans with loss of function mutations in either IL-10 or IL-10R develop 
severe spontaneous colitis40. Similarly, Il10−/− and Il10rb−/− mice develop spontaneous colitis due to 
uncontrolled inflammation36,41,42. While IL-10 production by macrophages is dispensable for progression 
of colitis, IL-10R signaling in macrophages is critically involved in controlling the progression of auto-
immune colitis in mice43. A recent report suggested that uncontrolled NLRP3 inflammasome activation 
promotes the spontaneous colitis observed in Il10−/− mice44. Gut microbiota and associated endotoxin 
are major sources of stimulation that promote inflammation and spontaneous colitis in Il10−/− mice45. 
Our study herein provides molecular insights into how the IL-10/IL-10R signaling axis regulates NLRP3 
inflammasome activation in macrophages during acute and chronic LPS/ATP stimulation, and helps to 
identify novel targets that could be exploited to treat colitis.
In conclusion, we have uncovered a novel regulatory pathway involving IL-10 in dampening NLRP3 
inflammasome activation. Mechanistically, our studies demonstrate that IL-10 diminishes protein expres-
sion levels of NLRP3 and pro-IL-1β , which ultimately impacts caspase-8 activation to regulate activation 
of the NLRP3 inflammasome. Conceptually, our study is the first to uncover how NLRP3 inflammasomes 
are modulated during acute and chronic TLR stimulations. Therapeutically, IL-10 can be specifically tar-
geted to either attenuate or activate NLRP3 inflammasome in the treatment of several autoinflammatory 
and infectious diseases.
Methods
Guideline statement. All methods used in this study are in accordance to protocols approved by St. 
Jude Children’s Research Hospital. All studies and experiments were conducted under guidelines and 
protocols approved by St. Jude Children’s Research Hospital on the Use and Care of Animals Committee.
Mice. C57BL/6 were purchased from Jackson laboratory and bred at St. Jude Children’s Research 
Hospital in a specific pathogen-free animal care facility. Nlrp3−/−3 and Il10raMdel 28 (macrophage specific 
deletion of IL-10Rα ) mice have been previously described. Animal studies were conducted under proto-
cols approved by St. Jude Children’s Research Hospital on the Use and Care of Animas.
Macrophage differentiation and stimulation. Bone marrow-derived macrophages (BMDMs) were 
prepared as described previously24. In brief, bone marrow cells were grown in L-cell-conditioned IMDM 
medium supplemented with 10% FBS, 1% non-essential amino acid and 1% penicillin-streptomycin for 5 
days to differentiate into macrophages. On day 5 BMDMs were seeded in 6-well cell culture plates. On the 
next day BMDMs were stimulated with LPS (Invivogen- LPS-SM) (20 ng/ml) or PAM3CSK4 (1 μ g/ml) 
for the indicated hours of time followed by 5 mM ATP or 20 μ M nigericin for the last 30 minutes. In 
some experiments, BMDMs were pretreated for 30 minutes with mouse recombinant IL-10 (50 ng/mL- 
Peprotech) or anti-mouse IL-10R mAb (1 μ g/mL- BioxCell) before LPS/PAM3CSK4 stimulation.
In supernatant transfer experiments, supernatants from control (0 h sups), 4 h LPS treated (4 h sups) 
and 24 h LPS treated (24 h sups) BMDMs were transferred to fresh unstimulated BMDMs. These BMDMs 
were then stimulated with 20 ng/ml LPS for 4 h followed by ATP for the last 30 minutes. Caspase-1 
activation was determined in the cell lysates and IL-1β and IL-18 production were determined in the 
supernatants by ELISA.
Western blotting. Samples for immunoblotting were prepared by combining cell lysates with culture 
supernatants. Samples were denatured in loading buffer containing SDS and 100 mM DTT and boiled 
for 5 min. SDS-PAGE-separated proteins were transferred to PVDF membranes and immunoblotted 
with primary antibodies against caspase-1 (Adipogen, AG-20B-0042), pro-caspase-8 (Enzo Life Sciences, 
1G12), cleaved caspase-8 (Cell Signaling Technology, D5B2), NLRP3 (Adipogen, AG-20B-0014), IL-1β 
(Cell Signaling Technology, D3H1Z), and GAPDH (Cell Signaling Technology, D16H11) followed by sec-
ondary anti-rabbit or anti-rat or anti- mouse HRP antibodies (Jackson Immuno Research Laboratories), 
as previously described24.
Cytokine analysis. Concentrations of cytokines and chemokines were determined by multiplex 
ELISA (Millipore), or classical ELISA for IL-1β (eBioscience) and IL-18 (MBL international). ELISA 
data without statistical analysis were presented as mean ± s.e.m. of duplicate/triplicate technical repeats 
and all of these experiments were performed at least three times. For ELISA data with statistical analysis 
and showing significance, ELISA data were taken from three-five independent experiments.
Flow cytometry. BMDMs were stimulated with 20 ng LPS for indicated hours. Cells were then stained 
with anti-IL10R-PE or Isotype-PE control antibody and analyzed by flow cytometry.
Mouse Cytokine Array. IL-10, CCL1 and several other inflammatory cytokines were determined 
using mouse cytokine array kit by following manufacturer’s protocol (R&D Systems).
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Statistical Analysis. All data are represented as mean ± s.e.m. and all experiments were repeated at 
least two-three times before being reported.
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